H.C. Wainwright raised its price target for Liquidia Technologies (NASDAQ: LQDA) to $75. This represents an increase from the previous $67 target. The firm reaffirmed its Buy rating.
Analysts cite a recent Supreme Court ruling involving Hikma Pharmaceuticals and Amarin as a positive indicator. This legal precedent likely benefits Liquidia’s own ongoing patent litigation.
Liquidia recently reported its third consecutive profitable quarter. Robust sales of the pulmonary hypertension drug YUTREPIA drove these financial results. The stock currently trades near its 52-week high.